

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of : Meade, C. et al. ) Art Unit: 1614  
U.S. Appln. No. : 10/611,717 ) Examiner: Spivack, P.G.  
Confirmation No. : 7385  
U.S. Filing Date : 07/01/2003  
Title of Invention : New pharmaceutical compositions based on novel anticholinergics  
and p38 kinase inhibitors  
Attny. Docket No.: 1/1366

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**Response to Restriction Requirement**


Sir:

This paper is in response to the restriction requirement dated 06/09/2004.

In the restriction requirement, the Examiner has required election of a single species for examination purposes.

Applicants hereby elect without traverse the following species:

Example 1, page 162:



1-[5-*tert*-butyl-2-*p*-tolyl-2H-pyrazol-3-yl]-3-[4-(2-morpholin-4-yl-ethoxy)naphthalen-1-yl]-urea.


Claims 1-6 in-part, 10, 15-27 in-part.

Applicants respectfully request that the Examiner identify the scope of the search in the next paper in order to facilitate applicants filing any necessary divisional applications.


Applicants reserve the right to file in one or more divisional applications any nonelected subject matter in this case without prejudice under 35 USC 121.

**Certificate of Mailing Under 37 C.F.R. § 1.8(a)**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to  
Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450



Anthony P. Bottino  
Reg. No. 41,629



Dated

Respectfully submitted,



Anthony P. Bottino  
Registration No. 41,629  
Attorney for Applicants

BOEHRINGER INGELHEIM CORPORATION  
Patent Department  
900 Ridgebury Road/P.O. Box 368  
Ridgefield, CT 06877  
Telephone: (203) 791-6764  
Facsimile: (203) 798-4408